At the news
? BULLISHIMPACT 7/10 6-K filed Jul 31, 2026 at 06:54 ET
AstraZeneca's Datroway (datopotamab deruxtecan) received EU approval as monotherapy for 1st-line metastatic triple-negative breast cancer (TNBC) in patients ineligible for immunotherapy, based on the TROPION-Breast02 Phase III trial showing a 5.0-month median overall survival improvement (23.7 vs 18.7 months, HR 0.79) and a 43% reduction in progression/death risk. This expands Datroway's EU label to two breast cancer indications and positions it as the only TROP2-directed ADC with an overall survival benefit in this setting, reinforcing AstraZeneca's oncology growth trajectory.
- EU approval for 1st-line metastatic TNBC in patients not candidates for PD-1/PD-L1 inhibitor therapy.
- Approval based on TROPION-Breast02 Phase III trial: median OS 23.7 months (Datroway) vs 18.7 months (chemotherapy); HR 0.79 (p=0.0291).
- Risk of disease progression or death reduced by 43% (HR 0.57; p<0.0001); ORR 62.5% vs 29.3%.
- Datroway now approved for two breast cancer indications in the EU (HR+/HER2- and TNBC).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access